| Cold atmospheric plasma-treated PBS eliminates immunosuppressive pancreatic stellate cells and induces immunogenic cell death of pancreatic cancer cells J Van Loenhout, T Flieswasser, L Freire Boullosa, J De Waele, ... Cancers 11 (10), 1597, 2019 | 96 | 2019 |
| Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer M Versteven, JMJ Van den Bergh, E Marcq, ELJ Smits, VFI Van Tendeloo, ... Frontiers in immunology 9, 394, 2018 | 89 | 2018 |
| Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma E Marcq, V Siozopoulou, J De Waele, J van Audenaerde, K Zwaenepoel, ... Oncoimmunology 6 (1), e1261241, 2017 | 88 | 2017 |
| Cold atmospheric plasma treatment of melanoma and glioblastoma cancer cells S Vermeylen, J De Waele, S Vanuytsel, J De Backer, J Van der Paal, ... Plasma Processes and Polymers 13 (12), 1195-1205, 2016 | 76 | 2016 |
| Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells JRM Van Audenaerde, J De Waele, E Marcq, J Van Loenhout, E Lion, ... Oncotarget 8 (34), 56968, 2017 | 65 | 2017 |
| Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients E Marcq, J De Waele, J Van Audenaerde, E Lion, E Santermans, N Hens, ... Oncotarget 8 (52), 89722, 2017 | 61 | 2017 |
| Targeting immune checkpoints: New opportunity for mesothelioma treatment? E Marcq, P Pauwels, JP van Meerbeeck, ELJ Smits Cancer Treatment Reviews 41 (10), 914-924, 2015 | 57 | 2015 |
| Poly (I: C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade J De Waele, E Marcq, JRM Van Audenaerde, J Van Loenhout, C Deben, ... Oncoimmunology 7 (3), e1407899, 2018 | 50 | 2018 |
| NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects V Siozopoulou, E Smits, K De Winne, E Marcq, P Pauwels Diagnostics 11 (3), 478, 2021 | 36 | 2021 |
| Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment JRM Van Audenaerde, E Marcq, B von Scheidt, AS Davey, AJ Oliver, ... Clinical & translational immunology 9 (8), e1165, 2020 | 30 | 2020 |
| Immune checkpoint inhibitory therapy in sarcomas: is there light at the end of the tunnel? V Siozopoulou, A Domen, K Zwaenepoel, A Van Beeck, E Smits, ... Cancers 13 (2), 360, 2021 | 28 | 2021 |
| Spontaneous Healing of Mycobacterium ulcerans Lesions in the Guinea Pig Model R Silva-Gomes, E Marcq, G Trigo, CM Goncalves, A Longatto-Filho, ... PLoS neglected tropical diseases 9 (12), e0004265, 2015 | 23 | 2015 |
| The search for an interesting partner to combine with PD-L1 blockade in mesothelioma: focus on Tim-3 and LAG-3 E Marcq, JRM Van Audenaerde, J De Waele, C Merlin, P Pauwels, ... Cancers 13 (2), 282, 2021 | 21 | 2021 |
| Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression V Siozopoulou, E Marcq, J Jacobs, K Zwaenepoel, C Hermans, J Brauns, ... Cancer Immunology, Immunotherapy 68, 1573-1583, 2019 | 17 | 2019 |
| The effect of local non‐thermal plasma therapy on the cancer‐immunity cycle in a melanoma mouse model A Lin, J De Backer, D Quatannens, B Cuypers, H Verswyvel, ... Bioengineering & Translational Medicine 7 (3), e10314, 2022 | 16 | 2022 |
| Building a bridge between chemotherapy and immunotherapy in malignant pleural mesothelioma: investigating the effect of chemotherapy on immune checkpoint expression E Marcq, JRM Van Audenaerde, J De Waele, J Jacobs, J Van Loenhout, ... International journal of molecular sciences 20 (17), 4182, 2019 | 11 | 2019 |
| Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer Y Debie, JRM Van Audenaerde, T Vandamme, L Croes, LA Teuwen, ... Clinical Cancer Research 29 (3), 635-646, 2023 | 9 | 2023 |
| Dendritic cells and programmed Death-1 blockade: a joint venture to combat cancer. Front Immunol. 2018; 9: 394 M Versteven, JMJ Van den Bergh, E Marcq, ELJ Smits, VFI Van Tendeloo, ... | 9 | 2018 |
| Auranofin synergizes with the PARP inhibitor olaparib to induce ROS-mediated cell death in mutant p53 cancers L Freire Boullosa, J Van Loenhout, T Flieswasser, C Hermans, C Merlin, ... Antioxidants 12 (3), 667, 2023 | 8 | 2023 |
| Recent advances of immune checkpoint inhibition and potential for (Combined) TIGIT blockade as a new strategy for malignant pleural mesothelioma S Rovers, A Janssens, J Raskin, P Pauwels, JP van Meerbeeck, E Smits, ... Biomedicines 10 (3), 673, 2022 | 6 | 2022 |
